Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DnaJ heat shock protein family member C19 pseudogene 4 (DNAJC19P4) is classified as a pseudogene, specifically designated as the fourth pseudogene related to the DnaJ heat shock protein (Hsp40) family member C19[1][3]. Pseudogenes are DNA sequences that arise from previously functional protein-coding genes but are no longer capable of producing functional proteins due to disabling mutations, truncations, or loss of key regulatory elements[5][8]. DNAJC19P4 has no known functional protein product, no reported biological activity, and no evidence supporting its involvement as a therapeutic target, such as a receptor, enzyme, transporter, or transcription factor[1][3]. Pseudogenes, while sometimes transcribed, rarely encode proteins, and there is no indication that DNAJC19P4 plays any regulatory or disease-associated role[3][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DnaJ heat shock protein family member C19 pseudogene 4 (DNAJC19P4).